NLS Collaboration

In the picturesque expanse of the Nordic region, a history of collaboration and shared values has woven a tapestry of unity that extends across borders and sectors. From the era of explorations to modern scientific frontiers, Nordic countries have fostered collaborative efforts to achieve scientific advancements, weathering challenges and celebrating successes. The roots of cross-border […]

For the past decade, Nordic Life Science Days (NLSDays) has been building business partnerships, highlighting innovations and showcasing all that the Nordic countries have to offer in the life science field. For its 10th anniversary, 29-30 November in Copenhagen, the planners expect to do that and more, including focusing on the latest developments in medicine […]

This Nobel Prize-special issue includes for example exclusive interviews with Medicine Laureate Katalin Karikó and Chemistry Laureate Moungi Bawendi. The Nobel Prize-special section also includes articles about the other Nobel Prize Laureates in Medicine and Chemistry and in-depth articles about nucleoside base modifications and mRNA, quantum dots and attosecond physics, and their applications within life […]

The Finnish Genomics initiative FinnGen has entered its next phase, backed by EUR 52 million of new funding. Since its initiation in 2017, FinnGen has developed into one of the world’s leading biobank-based genomic research projects. It has completed the construction of a research resource that integrates genomic information from half a million Finnish biobank […]

The company has entered into a collaboration agreement with DiaUnion, a center of excellence in type 1 diabetes, to identify participants for the DiaPrecise trial. DiaPrecise is an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd in children at risk of developing type 1 diabetes who also carry the […]

AstraZeneca has announced a collaboration and investment agreement with the French clinical-stage biotechnology company Cellectis to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis gene editing technologies and manufacturing capabilities, to design […]